Canada markets open in 6 hours 7 minutes

IQVIA Holdings Inc. (IQV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
231.22-0.72 (-0.31%)
At close: 4:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close231.94
Bid0.00 x 900
Ask231.62 x 900
Day's Range229.35 - 231.74
52 Week Range128.52 - 237.47
Avg. Volume963,591
Market Cap44.316B
Beta (5Y Monthly)1.46
PE Ratio (TTM)110.10
EPS (TTM)2.10
Earnings DateJul. 20, 2021 - Jul. 26, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est256.32
  • 3 Reasons Why Growth Investors Shouldn't Overlook IQVIA (IQV)

    3 Reasons Why Growth Investors Shouldn't Overlook IQVIA (IQV)

    IQVIA (IQV) could produce exceptional returns because of its solid growth attributes.

  • Business Wire

    IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

    IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.

  • Business Wire

    Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study

    Global spending on medicines — using invoice price levels — is expected to grow at 3-6 percent CAGR through 2025 to reach about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report The Global Spending and Usage of Medicines released by the IQVIA™ Institute for Human Data Science. The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion, largely focused on the initial wave of vaccinations to be completed by 2022. In subsequent years, booster shots are expected to be required on a biannual basis as the durability of immunity and the continued emergence of viral variants make an endemic virus the most likely outcome.